AR061136A1 - Procedimiento - Google Patents
ProcedimientoInfo
- Publication number
- AR061136A1 AR061136A1 ARP070102352A ARP070102352A AR061136A1 AR 061136 A1 AR061136 A1 AR 061136A1 AR P070102352 A ARP070102352 A AR P070102352A AR P070102352 A ARP070102352 A AR P070102352A AR 061136 A1 AR061136 A1 AR 061136A1
- Authority
- AR
- Argentina
- Prior art keywords
- gene expression
- refers
- expression profiles
- microdispositions
- tumors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente se refiere a perfiles de expresion de genes, microdisposiciones que comprenden secuencias de ácido nucleico que representan perfiles de expresion de genes y nuevos kits y procedimientos de diagnostico. La presente además se refiere al tratamiento de poblaciones específicas de, por ejemplo, pacientes de cáncer, como se caracteriza por su perfil de expresion génica, que padecen tumores que expresan Mage.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0610949A GB0610949D0 (en) | 2006-06-02 | 2006-06-02 | Method |
GB0700761A GB0700761D0 (en) | 2007-01-15 | 2007-01-15 | Method |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061136A1 true AR061136A1 (es) | 2008-08-06 |
Family
ID=38801855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102352A AR061136A1 (es) | 2006-06-02 | 2007-05-31 | Procedimiento |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100021424A1 (es) |
EP (23) | EP2390366A1 (es) |
JP (1) | JP2009538607A (es) |
KR (1) | KR20090017655A (es) |
AR (1) | AR061136A1 (es) |
AU (1) | AU2007256383B2 (es) |
BR (1) | BRPI0712497A2 (es) |
CA (1) | CA2653949A1 (es) |
CL (1) | CL2007001571A1 (es) |
EA (1) | EA200802242A1 (es) |
ES (1) | ES2539042T3 (es) |
MX (1) | MX2008015372A (es) |
PE (1) | PE20080742A1 (es) |
TW (1) | TW200817680A (es) |
WO (1) | WO2007140958A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2227558A1 (en) * | 2007-11-30 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Method for classifying cancer patients as responder or non-responder to immunotherapy |
GB0816867D0 (en) * | 2008-09-15 | 2008-10-22 | Glaxosmithkline Biolog Sa | Method |
GB2466025A (en) * | 2008-12-08 | 2010-06-09 | Univ Francois Rabelais De Tour | C3/ITGAM polymorphisms and cancer prognosis |
GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
US20120258076A1 (en) * | 2009-12-16 | 2012-10-11 | Hitachi Chemical Research Center, Inc. | Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers |
EP2380991A1 (en) | 2010-04-20 | 2011-10-26 | Universitätsklinikum Hamburg-Eppendorf | Method of determining the metastatic potential of a tumor |
CN103299188B (zh) * | 2010-09-15 | 2017-03-15 | 阿尔玛克诊断有限公司 | 用于癌症的分子诊断试验 |
KR101287600B1 (ko) * | 2011-01-04 | 2013-07-18 | 주식회사 젠큐릭스 | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 |
US9926604B2 (en) | 2011-10-14 | 2018-03-27 | The Regents Of The University Of California | Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same |
PL2872646T3 (pl) * | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
EP3164069B1 (en) * | 2014-07-03 | 2020-09-16 | University Of Virginia Patent Foundation | Systems and methods for identifying and profiling muscle patterns |
WO2016049276A1 (en) * | 2014-09-25 | 2016-03-31 | Moffitt Genetics Corporation | Prognostic tumor biomarkers |
EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
JP6489900B2 (ja) * | 2015-03-30 | 2019-03-27 | 株式会社ジャパンディスプレイ | 入力装置及び表示装置 |
AU2016264623B2 (en) | 2015-05-20 | 2022-06-30 | Dana-Farber Cancer Institute, Inc. | Shared neoantigens |
CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
GB201908565D0 (en) * | 2019-06-14 | 2019-07-31 | Cray Innovation Ab | Method of stratifying subjects into sub-groups for therapeutic treatment |
CN114540504B (zh) * | 2022-04-27 | 2022-07-08 | 广州万德基因医学科技有限公司 | 用于预测肺鳞癌患者免疫疗效的标志物组及系统 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1001034B (el) * | 1989-07-21 | 1993-03-31 | Ortho Pharma Corp | Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
SK279188B6 (sk) | 1992-06-25 | 1998-07-08 | Smithkline Beecham Biologicals S.A. | Vakcínová kompozícia spôsob jej prípravy a použiti |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
ATE315088T1 (de) | 1998-02-05 | 2006-02-15 | Glaxosmithkline Biolog Sa | Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung |
DK1104306T3 (da) | 1998-08-10 | 2006-05-22 | Antigenics Inc | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf |
ES2348708T3 (es) | 1999-01-29 | 2010-12-13 | Corixa Corporation | Proteinas de fusion de her-2/neu. |
AU756398B2 (en) | 1999-03-11 | 2003-01-09 | Smithkline Beecham Biologicals (Sa) | Novel compounds |
HU229255B1 (en) | 1999-04-19 | 2013-10-28 | Smithkline Beecham Biolog | Vaccines |
DK1650221T3 (da) | 2000-02-23 | 2012-09-03 | Glaxosmithkline Biolog Sa | Nye forbindelser |
AUPR077900A0 (en) * | 2000-10-13 | 2000-11-09 | Tvw Telethon Institute For Child Health Research | Immunodiagnosis |
US20020076469A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
KR20030092003A (ko) * | 2001-02-26 | 2003-12-03 | 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) | 인터페론 조절 인자-1/인간 에스트로겐 수용체 융합단백질 및 암을 치료하기 위한 그의 용도 |
WO2002076469A1 (en) * | 2001-03-27 | 2002-10-03 | Baylor College Of Medicine | A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity |
DE10127572A1 (de) * | 2001-05-30 | 2002-12-05 | Pathoarray Gmbh | Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen |
US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US7718387B2 (en) * | 2001-09-20 | 2010-05-18 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
WO2003050257A2 (en) * | 2001-12-06 | 2003-06-19 | University Of Florida | Targeting leukemia cells |
DE60234386D1 (de) | 2002-02-04 | 2009-12-24 | Corixa Corp | Neue immuneffektor-verbindungen |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
ES2285174T3 (es) | 2002-06-11 | 2007-11-16 | Glaxosmithkline Biologicals S.A. | Composiciones inmunogenicas. |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
WO2004076565A2 (en) * | 2003-02-25 | 2004-09-10 | Technical Knockout, Inc. | Improved coated weight plates, dumbbells and method of manufacture |
JP2006524502A (ja) * | 2003-02-28 | 2006-11-02 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 乳癌の発現プロファイル及び使用法 |
US20050095607A1 (en) * | 2003-03-07 | 2005-05-05 | Arcturus Bioscience, Inc. University Of Louisville | Breast cancer signatures |
EP1608964A4 (en) | 2003-03-14 | 2009-07-15 | Peter Maccallum Cancer Inst | PROFILING THE EXPRESSION OF TUMORS |
US20040241725A1 (en) * | 2003-03-25 | 2004-12-02 | Wenming Xiao | Lung cancer detection |
US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
WO2004105573A2 (en) * | 2003-05-21 | 2004-12-09 | The Wistar Institute Of Anatomy And Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
EP1631689A2 (en) * | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
MXPA05012939A (es) | 2003-05-30 | 2006-05-17 | Astrazeneca Uk Ltd | Procedimiento. |
WO2005001138A2 (en) * | 2003-06-18 | 2005-01-06 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
CA2893995A1 (en) * | 2003-06-27 | 2005-01-06 | International Institute Of Cancer Immunology, Inc. | Method of diagnosis of cancer |
DE602004015626D1 (de) * | 2003-08-28 | 2008-09-18 | Ipsogen | Bei brustkrebs |
EP1677733A4 (en) * | 2003-10-03 | 2007-09-19 | Bayer Pharmaceuticals Corp | GENE EXPRESSION PROFILES AND METHOD OF USE |
WO2005044999A2 (en) * | 2003-11-05 | 2005-05-19 | New England Medical Center Hospitals, Inc. | Treatment with immunoregulatory t cells |
WO2005054496A1 (ja) * | 2003-12-02 | 2005-06-16 | Orient Cancer Therapy Co., Ltd. | 細胞動態の検査方法 |
WO2005059543A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963) |
CA2555346C (en) * | 2004-02-09 | 2015-04-21 | Fuso Pharmaceutical Industries, Ltd. | Method of detecting nucleic acid and utilization thereof |
US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
US7332281B2 (en) * | 2004-04-27 | 2008-02-19 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
DE602005023488D1 (de) * | 2004-06-17 | 2010-10-21 | Mannkind Corp | Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie |
WO2006012641A2 (en) * | 2004-07-30 | 2006-02-02 | Oregon Health And Science University | Methods for detecting and treating autoimmune disorders |
WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
US20060110371A1 (en) * | 2004-11-23 | 2006-05-25 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
WO2006060653A2 (en) | 2004-11-30 | 2006-06-08 | Veridex Llc | Lung cancer prognostics |
US20070059720A9 (en) * | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
WO2006073982A2 (en) * | 2004-12-30 | 2006-07-13 | Regents Of The University Of California | Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein |
US7666595B2 (en) | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
GB0504302D0 (en) | 2005-03-02 | 2005-04-06 | Univ Dublin | Markers for melanoma |
EP1863930A2 (en) | 2005-04-01 | 2007-12-12 | NCC Technology Ventures Pte Limited | Materials and methods relating to breast cancer classification |
CA2604844A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Cancer-related genes |
WO2006113678A2 (en) * | 2005-04-15 | 2006-10-26 | Oncomethylome Sciences, Inc. | Methylation markers for diagnosis and treatment of cancers |
CA2608359A1 (en) | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
EP1904845A4 (en) * | 2005-07-07 | 2009-11-25 | David E Kohne | IMPROVED RESULTS AND APPLICATION OF COMPARISON EXAMPLES OF PROTEIN EXPRESSIONS |
WO2007042286A1 (en) * | 2005-10-11 | 2007-04-19 | Merck Patent Gmbh | Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
-
2007
- 2007-05-31 EP EP11163719A patent/EP2390366A1/en not_active Withdrawn
- 2007-05-31 JP JP2009512510A patent/JP2009538607A/ja active Pending
- 2007-05-31 EP EP11162325A patent/EP2390354A1/en not_active Withdrawn
- 2007-05-31 ES ES10159376.2T patent/ES2539042T3/es active Active
- 2007-05-31 EP EP11163252A patent/EP2390357A1/en not_active Withdrawn
- 2007-05-31 EP EP11162323A patent/EP2392672A1/en not_active Withdrawn
- 2007-05-31 BR BRPI0712497-0A patent/BRPI0712497A2/pt not_active IP Right Cessation
- 2007-05-31 EP EP11162320A patent/EP2392671A1/en not_active Withdrawn
- 2007-05-31 EP EP11163261A patent/EP2390358A1/en not_active Withdrawn
- 2007-05-31 MX MX2008015372A patent/MX2008015372A/es not_active Application Discontinuation
- 2007-05-31 EP EP07725789A patent/EP2032719A2/en not_active Withdrawn
- 2007-05-31 WO PCT/EP2007/004915 patent/WO2007140958A2/en active Application Filing
- 2007-05-31 EP EP11163268A patent/EP2392675A1/en not_active Withdrawn
- 2007-05-31 CA CA002653949A patent/CA2653949A1/en not_active Abandoned
- 2007-05-31 AU AU2007256383A patent/AU2007256383B2/en not_active Ceased
- 2007-05-31 EP EP11163271A patent/EP2390361A1/en not_active Withdrawn
- 2007-05-31 EP EP11163726A patent/EP2390369A1/en not_active Withdrawn
- 2007-05-31 EP EP11163713A patent/EP2390363A1/en not_active Withdrawn
- 2007-05-31 EP EP11163717A patent/EP2390365A1/en not_active Withdrawn
- 2007-05-31 EP EP11163716A patent/EP2390364A1/en not_active Withdrawn
- 2007-05-31 KR KR1020087031950A patent/KR20090017655A/ko not_active Application Discontinuation
- 2007-05-31 EP EP11163277A patent/EP2390362A1/en not_active Withdrawn
- 2007-05-31 AR ARP070102352A patent/AR061136A1/es not_active Application Discontinuation
- 2007-05-31 EP EP11163264A patent/EP2390360A1/en not_active Withdrawn
- 2007-05-31 EP EP11163263A patent/EP2390359A1/en not_active Withdrawn
- 2007-05-31 CL CL200701571A patent/CL2007001571A1/es unknown
- 2007-05-31 EP EP11163720A patent/EP2390367A1/en not_active Withdrawn
- 2007-05-31 EA EA200802242A patent/EA200802242A1/ru unknown
- 2007-05-31 PE PE2007000676A patent/PE20080742A1/es not_active Application Discontinuation
- 2007-05-31 EP EP10159376.2A patent/EP2258874B1/en active Active
- 2007-05-31 EP EP11163722A patent/EP2390368A1/en not_active Withdrawn
- 2007-05-31 TW TW096119645A patent/TW200817680A/zh unknown
- 2007-05-31 EP EP11162324A patent/EP2390353A1/en not_active Withdrawn
- 2007-05-31 EP EP11162327A patent/EP2390356A1/en not_active Withdrawn
- 2007-05-31 EP EP11162326A patent/EP2390355A1/en not_active Withdrawn
- 2007-05-31 EP EP11162329A patent/EP2392673A1/en not_active Withdrawn
- 2007-05-31 US US12/303,213 patent/US20100021424A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061136A1 (es) | Procedimiento | |
WO2012174256A3 (en) | Dna methylation profiles in cancer | |
WO2010073248A3 (en) | Gene expression signature for classification of tissue of origin of tumor samples | |
WO2005111211A3 (en) | Micronas and uses thereof | |
IN2012DN04944A (es) | ||
GB2459228A (en) | Exosome-associated microrna as a diagnostic marker | |
MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
WO2009111643A3 (en) | Microrna markers for recurrence of colorectal cancer | |
WO2010081001A3 (en) | Recurrent gene fusions in cancer | |
ES2527592T3 (es) | Métodos basados en microARN para el diagnóstico del cáncer de colon | |
NZ703824A (en) | Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell | |
EP2569453A4 (en) | Nucleic Acid ISOLATION METHOD | |
MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
WO2004066941A3 (en) | Expression profiles for colon cancer and methods of use | |
WO2008079269A3 (en) | Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom | |
MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
CA2840149C (en) | Methods and nucleic acids for determining the prognosis of a cancer subject | |
WO2007058968A3 (en) | Gene expression profiles and methods of use | |
SG179129A1 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
DE602006012995D1 (de) | Brustkrebsdiagnoseverfahren | |
WO2004078035A3 (en) | Expression profiles for breast cancer and methods of use | |
MX2013004747A (es) | Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson. | |
WO2009121878A3 (en) | In vitro diagnostic method for the diagnosis of somatic and ovarian cancers | |
WO2011021177A3 (en) | Compositions and methods for prognosis and treatment of prostate cancer | |
ATE513929T1 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |